Human albumin


Generic Medicine Info
Indications and Dosage
Intravenous
Neonatal hyperbilirubinaemia
Child: As human albumin 20% or 25% solution: 1 g/kg before or during exchange transfusion. Treatment recommendations may vary among countries and individual product (refer to detailed product or local treatment guidelines).

Intravenous
Hypoproteinaemia
Adult: As human albumin 25% solution: 200-300 mL; given at a rate not faster than 100 mL in 30-45 minutes. If slower infusion is desired, 200 mL human albumin 25% solution may be diluted with 300 mL of 10% dextrose solution and given via continuous drip at a rate of 100 mL/hour. Treatment and dosage recommendations may vary among countries and individual product (refer to detailed product or local treatment guidelines).

Intravenous
Hypovolaemia
Adult: For restoration and maintenance of circulating blood volume: Dosage requirement depends on the weight of the patient, severity of trauma or illness, and on continuing fluid and protein losses. Adjust the concentration of human albumin preparation, dosage, and infusion rate according to individual patient requirements. Low concentration (e.g. 4% or 5% solution) of human albumin is generally preferred for replacement of volume deficit. As human albumin 5% solution: Initially, 12.5-25 g; may repeat after 15-30 minutes if response is inadequate. Human albumin 20-25% solution is recommended if hypovolaemia is long-standing and hypoalbuminaemia exists accompanied by adequate hydration or oedema. Treatment and dosage recommendations may vary among countries and individual product (refer to detailed product or local treatment guidelines).
Child: As human albumin 5% solution: 0.5-1 g/kg (10-20 mL/kg) over 5-10 minutes. Treatment and dosage recommendations may vary among countries and individual product (refer to detailed product or local treatment guidelines).

Intravenous
Prevention of central volume depletion following paracentesis due to cirrhotic ascites
Adult: As human albumin 20% or 25% solution: Adjunct treatment: 8 g for every 1,000 mL of ascitic fluid removed. Treatment recommendations may vary among countries and individual product (refer to detailed product or local treatment guidelines).

Intravenous
Plasma volume expander in severe ovarian hyperstimulation syndrome
Adult: In patients who fail to achieve or maintain urine output and haemodynamic stability with 0.9% NaCl solution: As human albumin 20% or 25% solution: 50-100 g over 4 hours, repeated at 4- to 12-hour intervals as needed. Treatment recommendations may vary among countries and individual product (refer to detailed product or local treatment guidelines).
Reconstitution
Human albumin 20% or 25% solution: May be diluted in isotonic solution (e.g. 0.9% NaCl, 5% dextrose).
Incompatibility
Dilution with sterile water will produce a hypotonic solution that may cause haemolysis and acute renal failure.
Contraindications
Hypersensitivity. Heart failure with normal or increased intravascular volume, severe anaemia. Dilution with sterile water for inj.
Special Precautions
Patient with conditions where hypervolaemia and its consequences or haemodilution may increase the risk of adverse reactions (e.g. hypertension, oesophageal varices, pulmonary oedema, haemorrhagic diathesis, renal and post-renal anuria); severe traumatic brain injury, low cardiac reserve. Postoperative or injured patient. Avoid rapid infusion in patients with history of CV disease. Not recommended as a source of supplemental caloric protein in patients requiring nutritional support. Renal and hepatic impairment. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Severe allergic or anaphylactic reactions, coagulation abnormality, electrolyte imbalance (large volume replacement); cardiac, respiratory, or renal failure; increased intracranial pressure; hypervolaemia.
Cardiac disorders: Tachycardia, bradycardia.
Gastrointestinal disorders: Vomiting, nausea.
General disorders and administration site conditions: Chills, fever, chest tightness.
Nervous system disorders: Headache, tremor, dizziness.
Psychiatric disorders: Confusional state.
Respiratory, thoracic and mediastinal disorders: Stridor, bronchospasm, dyspnoea.
Skin and subcutaneous tissue disorders: Rash erythematosus, angioneurotic oedema, hyperhidrosis, urticaria.
Vascular disorders: Hypertension, hypotension, flushing.
IV/Parenteral: C
Monitoring Parameters
Regularly monitor electrolyte levels, haematocrit or Hb levels, urine output, central venous pressure, pulmonary artery wedge pressure, arterial blood pressure and pulse rate. Closely observe for heart failure and pulmonary oedema during administration.
Overdosage
Symptoms: CV overload (e.g. headache, dyspnoea, jugular vein congestion, increased blood pressure, raised central venous pressure, pulmonary oedema). Management: Discontinue infusion immediately. Carefully monitor haemodynamic parameters of the patient.
Drug Interactions

Action
Description: Human albumin, a protein colloid, is a normal component of the plasma and acts like physiological albumin, an essential factor in the regulation of plasma volume and tissue fluid balance. It increases intravascular oncotic pressure, causing movement of fluids from interstitial into intravascular space. It also binds and acts as a carrier of intermediate metabolites (including bilirubin), acidic drugs, fatty acids, hormones, enzymes, trace metals, and dyes.
Pharmacokinetics:
Excretion: Half-life: 15-20 days.
Storage
Store below 30°C. Do not freeze. Protect from light.
MIMS Class
Intravenous & Other Sterile Solutions
References
Albuminar-25 Solution (CSL Behring LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 10/11/2021.

Albunorm 20%, 200 g/L, Solution for Infusion (Medlink Marketing). MIMS Philippines. http://www.mims.com/philippines. Accessed 24/11/2021.

Albunorm 20%, 200 g/L, Solution for Infusion (Octapharma Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 23/11/2021.

Albunorm 25%, 250 g/L Solution for Infusion (Pharmaniaga Marketing Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 10/11/2021.

Albunorm 25%, 250 g/L, Solution for Infusion (Medlink Marketing). MIMS Philippines. http://www.mims.com/philippines. Accessed 24/11/2021.

Albunorm 25%, 250 g/L, Solution for Infusion (Octapharma Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 23/11/2021.

Albunorm 4%, 40 g/L, Solution for Infusion (Octapharma Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 23/11/2021.

Albunorm 5%, 50 g/L, Solution for Infusion (Octapharma Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 23/11/2021.

Albutein 20% Injection, Solution (Grifols USA, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 24/11/2021.

Albutein 25% Injection, Solution (Grifols USA, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 24/11/2021.

Anon. Albumin Human. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 23/11/2021.

Anon. Albumin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 10/11/2021.

Buckingham R (ed). Albumin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/11/2021.

Flexbumin Injection, Solution (Baxalta US Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 10/11/2021.

Human Albumin 200 g/L Baxter (Takeda Pharmaceuticals [Hong Kong] Ltd). MIMS Hong Kong. http://www.mims.com/hongkong. Accessed 24/11/2021.

Joint Formulary Committee. Albumin Solution. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/11/2021.

Zenalb 4.5%, 20% Solution (Germax Sdn. Bhd.). MIMS Malaysia. http://www.mims.com/malaysia. Accessed 24/11/2021.

Zenalb 4.5, 45 g/L Solution for Infusion (Bio Products Laboratory Limited). MHRA. https://products.mhra.gov.uk. Accessed 10/11/2021.

Disclaimer: This information is independently developed by MIMS based on Human albumin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
  • Albumin GCC
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in